HD-OPM Archive
Topics › Lp(a)

Lepodisiran siRNA cut Lp(a) by 93.9% at 400 mg in a 320-person NEJM trial

Louis Nervegna · May 07, 2025 · ♥ 15 reactions · 1 comments · original Facebook post
Lp(a)PCSK9, ezetimibe & newer drugs
AI summary & key facts

Luigi Fontana's summary of an NEJM trial of lepodisiran, an siRNA that blocks hepatic Lp(a) production. At the 400 mg dose Lp(a) fell by 93.9% placebo-adjusted, lasting up to a year, with only mild injection-site reactions. It offers a potential option for people with genetically high Lp(a) who cannot lower it with lifestyle or standard drugs.

(no text — see the shared post below)

Research cited

New Hope in Reducing Cardiovascular Risk Beyond LDL Cholesterol

Despite advances in lowering LDL cholesterol, many patients still face residual cardiovascular risk—one key contributor being elevated lipoprotein(a) [Lp(a)] levels, which are largely genetically determined and unaffected by lifestyle or traditional lipid-lowering therapies.

A recent study in NEJM highlights a promising breakthrough: lepodisiran, a small interfering RNA therapy that targets hepatic production of Lp(a).

In a randomized trial with 320 participants, lepodisiran significantly reduced serum Lp(a) concentrations. At the highest 400 mg dose, patients saw a placebo-adjusted reduction of 93.9% from baseline between days 60 to 180, with effects lasting up to a year. The therapy was well tolerated, with only mild injection-site reactions and no serious adverse events linked to the drug.

This could mark a major step forward in closing a critical gap in cardiovascular prevention strategies for those people who are born with genetically-elevated Lp(a).

#Cardiology #Innovation #LipoproteinA #CardiovascularHealth #ClinicalTrials #siRNA #Lepodisiran #Genetics #MedicalResearch

No photo description available.
← newer: At the same CAC score, exercisers have much lower heart attaolder: Lyon Heart Study (canola and olive oil) cut heart attacks an →